Story excerpt provided by Cincinnati Business Courier.
Written by Barrett J. Brunsman.
Airway Therapeutics, a Sharonville biotechnology company, has raised $6.3 million in bridge financing from new and existing investors to help develop a way to prevent and treat lung disease in premature babies.
The firm is developing a protein replacement therapy called AT-100, which is based on research conducted by Dr. Jeffrey Whitset at Cincinnati Children’s Hospital Medical Center.
Click here to read the complete article.
Originally published March 7, 2017.